Layer, Chiang, et al. Genome Biology
Amid Plans for $86.3M IPO, Fluidigm Discloses Novartis Prenatal Dx Deal
The company has filed a registration statement with the SEC for a proposed initial public offering worth up to $86.3 million, reviving plans for an IPO the company scrapped in September 2008 due to rapidly deteriorating economic conditions.
New to GenomeWeb? Register here quickly.